Trial Profile
Randomized, Controlled, Open Label, Clinical Trial for Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in Hepatocellular Carcinoma Patients With GALNT14-rs9679162-non-TT Genotype
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Adagloxad simolenin (Primary) ; OPT 821 (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 10 May 2021 Status changed from recruiting to discontinued. Reason the study was stopped: The biopsies in the first 5 screened patients were all negative for Globo-H, of which positive is required to include the patients.
- 02 Dec 2019 Status changed from not yet recruiting to recruiting.
- 30 Jan 2019 Planned initiation date changed from 1 Sep 2018 to 1 Mar 2019.